There is no fixed number of exposures that guarantees HIV infection, and there is no number that guarantees safety. The per-act risk varies enormously depending on the type of exposure, the viral load of the person living with HIV, and a web of biological factors on both sides of the encounter. A single contact can transmit the virus, and some people remain uninfected after hundreds of exposures. The most useful way to think about HIV transmission is not as a threshold you cross after a certain count, but as a probability that shifts dramatically with context.
Per-Act Risk Varies by Orders of Magnitude
A large systematic review pooled data from studies worldwide and estimated the per-act probability of HIV transmission for different exposure types. The numbers are expressed per 10,000 exposures, which makes the differences between routes strikingly clear. Blood transfusion with contaminated blood carries a risk of about 9,250 per 10,000, meaning infection is nearly certain from a single event. Mother-to-child transmission during pregnancy and delivery sits around 2,260 per 10,000 without treatment. For sexual transmission, receptive anal intercourse carries the highest per-act risk at roughly 138 per 10,000. Sharing needles for injection drug use comes in at about 63 per 10,000. Receptive vaginal intercourse averages around 8 per 10,000, insertive vaginal intercourse about 4 per 10,000, and insertive anal intercourse roughly 11 per 10,000.1PubMed Central. Estimating per-act HIV transmission risk: a systematic review
Those averages can be misleading if you read them as fixed odds. They are population-level estimates blending together encounters where viral load was high and encounters where it was undetectable, encounters with and without other sexually transmitted infections, encounters involving intact mucosal surfaces and encounters with micro-tears or ulcers. The actual probability for any given act can be many times higher or lower than the average, depending on the specific circumstances.
Why Viral Load Is the Single Biggest Variable
If one factor overwhelms all others, it is the amount of virus circulating in the blood and present in genital fluids. A meta-analysis of the largest studies on this question found that the risk of transmission roughly doubles for every tenfold increase in viral load.2PubMed Central. Impact of viral load and the duration of primary infection on HIV transmission: systematic review and meta-analysis That scaling effect means the difference between someone with a low viral load and someone with an extremely high one is not a small tweak to the odds; it can shift the per-act risk by a factor of ten or more.
The period of greatest danger is the first few weeks after someone acquires HIV, a window called acute infection. During this phase, viral concentrations in blood and genital secretions spike dramatically, sometimes exceeding ten million copies per milliliter of blood.3Journal of Trends in Life Sciences. Analyzing the Role of Viral Load Dynamics in Determining Transmission Risk Across Different Stages of HIV Infection The person is often asymptomatic or experiencing mild flu-like symptoms, with no reason to suspect they have been infected. Research suggests that infectiousness during acute infection may be as much as 26 times greater than during the long chronic phase that follows.4PubMed Central. Role of acute and early HIV infection in the sexual transmission of HIV This is one reason HIV continues to spread even in communities with high rates of testing: the window of peak transmissibility occurs before most people know they carry the virus.
On the other end of the spectrum, effective antiretroviral treatment suppresses viral load to undetectable levels in blood. Large studies of couples where one partner is living with HIV on treatment and maintains an undetectable viral load have recorded zero transmissions to the other partner, giving rise to the public health message “Undetectable = Untransmittable” (U=U). The per-act numbers quoted above were calculated across mixed populations and do not distinguish treated from untreated individuals. When the partner with HIV is on effective treatment, the per-act risk falls effectively to zero.
The Biological Bottleneck That Makes Infection Unlikely but Not Impossible
One reason per-act transmission probabilities for sexual contact are relatively low is that HIV faces a punishing gauntlet when it tries to cross a mucosal surface. The virus has to find and infect specific immune cells, primarily CD4+ T cells bearing the CCR5 co-receptor, through intact or near-intact tissue. Research using human tissue models has shown that HIV can penetrate vaginal immune cells quickly upon direct contact, fusing with CD4+ T cells in the tissue without needing to pass through intermediate cells first.5PubMed Central. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1 But “can” does not mean “does every time.” The virus has to land in the right spot, encounter the right cells, and establish a foothold before the local immune response clears it.
Studies of the genetics of newly transmitted virus reveal something striking: in the vast majority of sexual transmissions, infection is established by a single viral variant, called the transmitted/founder virus.6PubMed Central. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses7PubMed Central. Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission Even though millions of viral particles may be present in the transmission fluid, almost all of them fail to cross the mucosal barrier successfully. Only one gets through. This extreme bottleneck explains why the per-act probability for sexual exposure is measured in single digits per ten thousand rather than hundreds: the body’s defenses stop most attempts cold, and infection requires that one variant thread the needle perfectly.
Factors That Tilt the Odds
Beyond viral load and exposure route, several biological conditions can raise or lower the chance that a given encounter leads to infection.
Sexually transmitted infections are among the most important modifiers. Both ulcerative infections like herpes and non-ulcerative ones like chlamydia disrupt the mucosal lining and attract exactly the types of immune cells HIV targets to the site of exposure. The link between genital herpes (HSV-2) and HIV acquisition is especially well documented: as many as half of people newly infected with HIV have been found to also carry HSV-2.8PubMed Central. Prevalence of Sexually Transmitted Co-Infections in People Living with HIV/AIDS: Systematic Review with Implications for using HIV Treatments for Prevention You do not need an active visible sore; subclinical shedding of herpes virus can still cause the kind of microscopic tissue disruption that gives HIV an easier path in.
In women, the composition of vaginal bacteria matters more than most people realize. Bacterial vaginosis, a common condition where the protective lactobacillus bacteria are replaced by a more diverse mix of other organisms, has been consistently linked to about a 1.5 times higher risk of acquiring HIV.9PubMed Central. Vaginal Microbiota and Susceptibility to HIV The mechanism involves both thinning of the protective mucosal layer and local inflammation that draws HIV-susceptible cells closer to the surface.
Male circumcision reduces HIV acquisition risk for the insertive partner in vaginal sex by at least 60%. The inner foreskin tissue removed during circumcision contains a high density of HIV-susceptible CD4+ T cells and exists in an inflammatory microenvironment driven partly by the bacteria that thrive in the warm, moist sub-preputial space.10PubMed Central. The biology of how circumcision reduces HIV susceptibility: broader implications for the prevention field11Current HIV/AIDS reports. How Does Voluntary Medical Male Circumcision Reduce HIV Risk? Removing that tissue both eliminates the main entry point and shifts the remaining penile microbiome toward a less inflammatory state.
Something in Semen Makes the Virus More Infectious
An unexpected discovery has complicated the picture of sexual transmission. Semen contains naturally occurring protein fragments, particularly pieces of prostatic acid phosphatase, that spontaneously fold into structures called amyloid fibrils. These fibrils, given the name SEVI (Semen-derived Enhancer of Viral Infection), physically capture HIV particles and press them against target cells, dramatically boosting the efficiency of viral attachment and entry. Laboratory experiments have shown that SEVI can enhance HIV infectivity by up to 100,000-fold compared to virus alone.12PubMed Central. The Surprising Role of Amyloid Fibrils in HIV Infection13PubMed. Semen-derived amyloid fibrils drastically enhance HIV infection
That laboratory number does not translate directly to a 100,000-fold increase in real-world transmission, because lab conditions strip away the many other barriers the virus faces in vivo. But the finding helps explain something that had puzzled researchers for years: why sexual transmission of HIV occurs at all, given how few free virus particles typically survive in genital fluids. The amyloid fibrils essentially act as a shuttle, concentrating sparse virus onto susceptible cells in a way that free-floating virus could not achieve alone. This effect exists only in the presence of semen, which is one reason male-to-female and male-to-male transmission routes tend to carry higher per-act risks than female-to-male transmission.
Some People Seem Resistant to Infection
Researchers have long been fascinated by a small number of individuals who remain uninfected despite frequent, documented exposure to HIV. These people, sometimes called “highly exposed seronegatives” (HESN), include sex workers with thousands of unprotected encounters with HIV-positive partners and serodiscordant couples who had regular unprotected sex for years without the negative partner seroconverting.
Part of the explanation is genetic. A mutation called CCR5-delta32, when inherited from both parents, prevents the CCR5 co-receptor from appearing on the surface of immune cells. Since most sexually transmitted HIV strains depend on CCR5 to enter cells, people with two copies of this mutation are essentially resistant to those strains. Studies of hemophiliacs who were exposed to HIV-contaminated blood products but never became infected found a high frequency of CCR5-delta32 homozygosity, confirming the protective role of this mutation.14PubMed. High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1 The mutation is most common in people of Northern European descent, where roughly 1% of the population carries two copies. Having just one copy provides partial protection but does not make someone immune.
Genetics alone does not account for all HESN individuals, though. Research comparing the mucosal immune responses of HESN men to those of controls found that the HESN group had dampened innate immune reactivity in their rectal mucosa, despite having similar numbers of immune cells present.15PubMed Central. Highly Human Immunodeficiency Virus-Exposed Seronegative Men Have Lower Mucosal Innate Immune Reactivity This seems paradoxical: you might expect more immune activity to be protective. But remember that HIV targets activated immune cells. A calmer mucosal environment may offer fewer activated CD4+ T cells for the virus to infect. Broader reviews of HESN research point to innate immune factors, including natural killer cells and specific dendritic cells, as front-line defenses that raise the bar HIV has to clear to establish productive infection.16PubMed Central. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN)
The existence of HESN individuals does not mean anyone should assume they are personally resistant. True genetic resistance is rare, and the immune-mediated protection seen in other HESN individuals is partial and not well understood enough to be tested for in a clinic. For most people, the per-act risk estimates from population studies are the best guide to their own vulnerability.
How PrEP Changes the Calculation
Pre-exposure prophylaxis, or PrEP, involves HIV-negative people taking antiretroviral medication to prevent infection. It has reshaped the risk landscape for those who use it consistently. Across randomized controlled trials of oral tenofovir-based PrEP, intention-to-treat analyses showed risk reductions ranging from about 49% to 86%. When researchers looked specifically at participants who actually took the pills consistently, confirmed by drug-level testing, effectiveness climbed to 92–99%.17PubMed Central. Effectiveness of Pre-exposure Prophylaxis (PrEP) in the Prevention of Human Immunodeficiency Virus (HIV): A Systematic Review of Randomized Controlled Trials With Narrative Synthesis
Real-world data from France confirmed this pattern outside the controlled environment of clinical trials. When researchers analyzed PrEP use among thousands of individuals at risk, overall effectiveness was about 60%, but that number rose to 93% among those with high pill consumption and fell to nearly zero among those who took PrEP sporadically.18The Lancet Public Health. Real-world effectiveness of pre-exposure prophylaxis for HIV prevention in France: a nationwide case-control study The message is consistent: PrEP works extraordinarily well, but only when you actually take it. Injectable long-acting cabotegravir, given as an injection every two months instead of a daily pill, addresses the adherence challenge and has been shown to outperform daily oral PrEP in large trials.17PubMed Central. Effectiveness of Pre-exposure Prophylaxis (PrEP) in the Prevention of Human Immunodeficiency Virus (HIV): A Systematic Review of Randomized Controlled Trials With Narrative Synthesis
Why Low Per-Act Risk Does Not Mean Low Cumulative Risk
People sometimes hear that the per-act risk of vaginal intercourse is less than 1 in 1,000 and conclude that HIV is hard to get through heterosexual sex. That interpretation misunderstands how probability accumulates over repeated exposures. A modeling study estimated that for a serodiscordant couple having sex about 100 times per year, the cumulative annual probability of transmission was roughly 0.2% for female-to-male transmission, about 0.4% for male-to-female, and approximately 4.3% for male-to-male anal sex.19Lancet. Relation between HIV viral load and infectiousness: a model-based analysis Over five or ten years of an ongoing sexual relationship, or across many different partners over a lifetime, even a small per-act risk adds up.
There is also a deeper statistical wrinkle. Research on heterosexual transmission has shown that the per-act probability of transmission is not the same across all couples; the heterogeneity is extreme.20PubMed Central. Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse Some couples have much higher per-encounter transmission risk than the population average, while others have much lower. The factors driving this variation include the partner’s viral load, the presence or absence of STIs, genetic differences in susceptibility, and mucosal health. So the “average” per-act number is the average of a wide spread, not a tight cluster. If you happen to be at the high end of that spread because of factors you cannot see or test for, your personal risk per exposure may be several times higher than the published average.
Mother-to-Child Transmission and Breastfeeding
Transmission from mother to child during pregnancy, labor, or breastfeeding operates under different rules than sexual transmission. Without any intervention, the overall risk across pregnancy and delivery is roughly one in four to five. Antiretroviral treatment during pregnancy and around delivery has reduced this dramatically in countries with widespread access to healthcare.
Breastfeeding remains a significant transmission route. Despite the progress in reducing mother-to-child transmission globally, breastfeeding still accounts for close to half of pediatric HIV infections recorded each year.21PubMed Central. Mother-to-Child Transmission of HIV Through Breastfeeding Improving Awareness and Education: A Short Narrative Review This creates a painful dilemma in settings where the alternatives to breastfeeding, such as formula feeding with potentially contaminated water, carry their own serious health risks for infants. Current guidelines in many low-resource settings recommend breastfeeding with concurrent antiretroviral treatment for the mother, which substantially reduces but does not eliminate the risk of transmission through breast milk.
The Problem With Thinking in Averages
The deepest misconception about HIV transmission risk is that it can be captured in a single number per route. Every factor discussed above interacts with the others. A person exposed to a recently infected partner (high viral load) who also has untreated genital herpes (mucosal disruption) and is the receptive partner in anal sex (higher baseline risk) faces a per-act probability vastly higher than someone exposed to a partner on suppressive treatment through brief insertive vaginal contact. The difference between these scenarios is not double or triple; it can be a hundredfold or more. Published per-act numbers are useful as a rough guide to which routes are riskier than others, but they should not be used to calculate a personal “number of times until infection.” That number does not exist. The virus does not keep a running count. Each exposure is its own independent event, shaped by whichever combination of factors happens to be present at that moment.